$277 Million is the total value of Aquilo Capital Management, LLC's 15 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $40,272,000 | -4.6% | 1,218,515 | +1.7% | 14.52% | +0.8% |
| XBI | Sell | S&P BIOTECH ETF TRput | $39,660,000 | -28.8% | 500,000 | -33.3% | 14.30% | -24.8% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $34,544,000 | -4.6% | 524,268 | -26.8% | 12.45% | +0.8% |
| MRUS | Buy | MERUS N V | $30,187,000 | -9.7% | 1,507,109 | +2.0% | 10.88% | -4.7% |
| ARVN | Sell | ARVINAS INC | $29,886,000 | -8.0% | 671,745 | -13.0% | 10.77% | -2.8% |
| RGNX | Sell | REGENXBIO INC | $25,576,000 | -11.3% | 967,684 | -17.1% | 9.22% | -6.3% |
| QURE | Sell | UNIQURE NV | $15,786,000 | -12.8% | 841,471 | -13.4% | 5.69% | -7.9% |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $13,833,000 | +6.0% | 1,998,993 | +7.1% | 4.99% | +12.0% |
| SLN | New | SILENCE THERAPEUTICS PLCads | $12,675,000 | – | 1,263,125 | +100.0% | 4.57% | – |
| ARGX | ARGENX SEsponsored adr | $8,473,000 | -6.8% | 24,000 | 0.0% | 3.05% | -1.6% | |
| GMAB | Buy | GENMAB A/Ssponsored ads | $7,867,000 | +12.7% | 244,848 | +14.0% | 2.84% | +19.1% |
| KYMR | New | KYMERA THERAPEUTICS INC | $7,189,000 | – | 330,246 | +100.0% | 2.59% | – |
| SPRO | Sell | SPERO THERAPEUTICS INC | $6,806,000 | +72.6% | 3,403,210 | -36.0% | 2.45% | +82.2% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $4,642,000 | -33.6% | 4,036,280 | +8.0% | 1.67% | -29.8% |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $29,000 | -99.5% | 3,573 | -99.6% | 0.01% | -99.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.